University of Illinois College of Medicine at Peoria, 221 NE Glen Oak Ave, Peoria, IL, 61636, USA.
A.I. Analysis, Inc., 1425 Broadway #20-2656, Seattle, WA, 98122, USA.
Eur Radiol Exp. 2021 Oct 12;5(1):46. doi: 10.1186/s41747-021-00240-2.
Previous intraindividual comparative studies evaluating gadobutrol and gadoteridol for contrast-enhanced magnetic resonance imaging (MRI) of brain tumours have relied on subjective image assessment, potentially leading to misleading conclusions. We used artificial intelligence algorithms to objectively compare the enhancement achieved with these contrast agents in glioblastoma patients.
Twenty-seven patients from a prior study who received identical doses of 0.1 mmol/kg gadobutrol and gadoteridol (with appropriate washout in between) were evaluated. Quantitative enhancement (QE) maps of the normalised enhancement of voxels, derived from computations based on the comparison of contrast-enhanced T1-weighted images relative to the harmonised intensity on unenhanced T1-weighted images, were compared. Bland-Altman analysis, linear regression analysis and Pearson correlation coefficient (r) determination were performed to compare net QE and per-region of interest (per-ROI) average QE (net QE divided by the number of voxels).
No significant differences were observed for comparisons performed on net QE (mean difference -24.37 ± 620.8, p = 0.840, r = 0.989) or per-ROI average QE (0.0043 ± 0.0218, p = 0.313, r = 0.958). Bland-Altman analysis revealed better per-ROI average QE for gadoteridol-enhanced MRI in 19/27 (70.4%) patients although the mean difference (0.0043) was close to zero indicating high concordance and the absence of fixed bias.
The enhancement of glioblastoma achieved with gadoteridol and gadobutrol at 0.1 mmol/kg bodyweight is similar indicating that these agents have similar contrast efficacy and can be used interchangeably, confirming the results of a prior double-blind, randomised, intraindividual, crossover study.
先前评估用于脑肿瘤对比增强磁共振成像（MRI）的钆布醇和钆特醇的个体内比较研究依赖于主观图像评估，这可能导致误导性的结论。我们使用人工智能算法客观比较了这些造影剂在胶质母细胞瘤患者中的增强效果。
对先前一项研究中的 27 名患者进行评估，他们接受了相同剂量的 0.1mmol/kg 钆布醇和钆特醇（两次注射之间有适当的冲洗时间）。基于对比增强 T1 加权图像与未增强 T1 加权图像的匀场强度的比较，计算出标准化增强的体素的定量增强（QE）图。进行 Bland-Altman 分析、线性回归分析和 Pearson 相关系数（r）确定，以比较净 QE 和每个感兴趣区（ROI）平均 QE（净 QE 除以体素数量）。
在净 QE（平均差异-24.37±620.8，p=0.840，r=0.989）或 ROI 平均 QE（0.0043±0.0218，p=0.313，r=0.958）比较中未观察到显著差异。Bland-Altman 分析显示，在 19/27（70.4%）名患者中，钆特醇增强 MRI 的 ROI 平均 QE 更好，尽管平均差异（0.0043）接近零，表明高度一致性且不存在固定偏差。
0.1mmol/kg 体重的钆特醇和钆布醇在胶质母细胞瘤的增强效果相似，表明这些造影剂具有相似的对比效果，可以相互替代，这与先前的一项双盲、随机、个体内、交叉研究的结果一致。
